Disease · MONDO_0006843

macular holes

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. macular holes. Diseases, record MONDO_0006843. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006843

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: macular holes; Open Targets
Open Targets ID: MONDO_0006843; Open Targets
Other names: Macular hole (disorder), Retinal Perforations, macular hole; Open Targets
Disease Ontology: DOID:7633; Disease Ontology
NCI Thesaurus: C34795; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OCRIPLASMIN	CHEMBL2095222	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BRILLIANT BLUE G	CHEMBL4173394	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/80781	Drugs and targets
COL1A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1277	Drugs and targets
COL1A2	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1278	Drugs and targets
COL24A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/255631	Drugs and targets
COL27A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/85301	Drugs and targets
COL28A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/340267	Drugs and targets
COL2A1	Collagen	1	Collagen hydrolytic enzyme	Phase 3	https://conductscience.org/library/genes/1280	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00781859	Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.	Phase 3	326	2013-01-28	Vitreomacular Adhesion	OCRIPLASMIN	Its record names the disease	ClinicalTrials.gov
NCT00798317	Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.	Phase 3	326	2013-01-30	Vitreomacular Adhesion	OCRIPLASMIN	Its record names the disease	ClinicalTrials.gov
NCT01429441	Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole	Phase 3	220	2016-01-11	Vitreomacular Adhesion Including Macular Hole	OCRIPLASMIN	Its record names the disease	ClinicalTrials.gov
NCT02067013	Analysis of Aqueous and Vitreous Humor	Phase 2	45		Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01820520	Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery	Phase 3	22		Macular Hole, Epiretinal Membrane	BRILLIANT BLUE G	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ocriplasmin 125µg vs Placebo: serious adverse events	32 of 220	13 of 106	326	NCT00781859	Trial comparisons
Ocriplasmin 125ug vs Placebo: serious adverse events	33 of 245	11 of 81	326	NCT00798317	Trial comparisons
Ocriplasmin vs Sham: serious adverse events	49 of 146	27 of 74	220	NCT01429441	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34250257	DERIVED	1	PubMed
30350717	DERIVED	1	PubMed
26068086	DERIVED	2	PubMed
23033391	DERIVED	2	PubMed
22894573	DERIVED	2	PubMed
22879421	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006843

GET https://conductscience.org/api/diseases/v1/MONDO_0006843/targets?page=2

API reference For AI assistants